Age, life expectancy influence termination of PSA screening

April 26, 2012
Age, life expectancy influence termination of PSA screening

(HealthDay) -- Most primary care providers consider both a man's age and life expectancy in deciding whether to discontinue prostate-specific antigen (PSA) screenings, but multiple factors are involved in this decision, according to a study published online April 19 in Cancer.

Craig E. Pollack, M.D., M.H.S., from the Johns Hopkins School of Medicine in Baltimore, and colleagues surveyed 125 primary providers from a large, university-affiliated primary care practice regarding their current , factors that influence their decision to discontinue screening, and barriers to discontinuing screening.

The researchers found that 59.3 percent of the primary care providers took both age and into account in their decisions to discontinue PSA screening, compared with 12.2 percent who did not consider either. Provider characteristics or practice styles were not associated with taking patient age and life expectancy into account. The majority (66.4 percent) of providers reported difficulty in assessing life expectancy and they differed in the age at which they typically stopped screening patients. Patient expectation and were the most frequently cited barriers to discontinuing PSA screening, cited 74.4 and 66.4 percent of the time, respectively.

"Although age and life expectancy often figured prominently in decisions to use screening, providers faced multiple barriers to discontinuing routine ," the authors write.

Explore further: Prostate cancer screenings at VA hospitals don't follow guidelines for elderly, study says

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Mass prostate cancer screening doesn't reduce deaths: study

January 6, 2012

There's new evidence that annual prostate cancer screening does not reduce deaths from the disease, even among men in their 50s and 60s and those with underlying health conditions, according to new research led by Washington ...

Recommended for you

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

Savior of T-cells may be enemy of liver immune cells

April 24, 2017

Researchers at Houston Methodist demonstrated that a surface protein called OX40, responsible for keeping one type of immune system cell alive, can trigger the death of liver immune cells, in turn starting a chain reaction ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.